13F-HR filed by Ally Bridge Group (NY) LLC
Ally Bridge Group (NY) LLC filed this 13F-HR for the quarter ended 2025-06-30, filed 2025-08-14, with 24 holding rows worth $120,180,084.
- Accession
- 0000950123-25-008419
- Filer
- CIK 1822947
- Filed
- 2025-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2025
A holdings report, 24 entries on the cover page, a total value of $120,180,084 stated on the cover page (in dollars after the unit check, H1), rows summing to $120,180,084 with VALUE read as dollars as filed, 13F file number 028-20834. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerFan Yu 028-20833
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| VERONA PHARMA PLC | 925050106 | SPONSORED ADS | 160,701 | $15,199,101 | dollars as filed | |
| SOLENO THERAPEUTICS INC | 834203309 | COM | 178,819 | $14,981,456 | dollars as filed | |
| LENZ THERAPEUTICS INC | 52635N103 | COM | 343,322 | $10,062,768 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 140,208 | $7,374,941 | dollars as filed | |
| ULTRAGENYX PHARMACEUTICAL IN | 90400D908 | CALL | 1,600 | $5,817,600 | dollars as filed | |
| ENLIVEN THERAPEUTICS INC COM | 29337E102 | Stock | 281,394 | $5,644,764 | dollars as filed | |
| ORIC PHARMACEUTICALS INC | 68622P109 | COM | 485,629 | $4,929,134 | dollars as filed | |
| REPLIMUNE GROUP INC | 76029N106 | COMMON STOCK | 528,491 | $4,909,681 | dollars as filed | |
| TARSUS PHARMACEUTICALS INC | 87650L103 | COMMON STOCK | 121,182 | $4,909,083 | dollars as filed | |
| INSMED INC COM PAR $.01 | 457669307 | Stock | 47,710 | $4,801,534 | dollars as filed | |
| MIND MEDICINE MINDMED INC | 60255C885 | COM NEW | 726,172 | $4,712,856 | dollars as filed | |
| GERON CORP | 374163103 | COM | 3,251,475 | $4,584,580 | dollars as filed | |
| COMPASS PATHWAYS PLC | 20451W101 | SPONSORED ADS | 1,485,000 | $4,158,000 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 293,986 | $3,862,976 | dollars as filed | |
| AVIDITY BIOSCIENCES INC COM | 05370A108 | Stock | 132,744 | $3,769,930 | dollars as filed | |
| SOLID BIOSCIENCES INC | 83422E204 | COMMON STOCK | 724,000 | $3,525,880 | dollars as filed | |
| LEXEO THERAPEUTICS INC | 52886X107 | COMMON STOCK | 867,302 | $3,486,554 | dollars as filed | |
| PRAXIS PRECISION MEDICINES I | 74006W207 | COM NEW | 80,880 | $3,401,004 | dollars as filed | |
| TECTONIC THERAPEUTIC INC | 878972108 | COMMON STOCK | 163,683 | $3,252,381 | dollars as filed | |
| KORRO BIO INC | 500946108 | COMMON STOCK | 154,223 | $1,926,245 | dollars as filed | |
| WHITEHAWK THERAPEUTICS INC | 00032Q104 | CMN | 817,939 | $1,529,546 | dollars as filed | |
| ATYR PHARMA INC | 002120202 | COM NEW | 287,720 | $1,458,740 | dollars as filed | |
| MONOPAR THERAPEUTICS INC | 61023L207 | COMMON STOCK | 34,537 | $1,235,734 | dollars as filed | |
| PROMIS NEUROSCIENCES INC | 74346M406 | COM NEW | 1,334,428 | $645,596 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-25-008419 | this filing | 2025-08-14 | acceptance time not in the bulk data set |